RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals An application of Accelerated Approval in the early stage of disease in pancreatic would result in the commercialization and marketing of pelareorep, which in turn would producr a revenue stream that would be more than sufficient for ONCY to run follow-on Accelerated Approvals and confirmatory Phase 3 clinical trials in other indications, that would create even greater cash flows from the expansion of approved immuno-therapeutic indications with pelareorep in combination with immune checkpoint inhibitors and other I/O agents.
Before this even happens ONCY may be acquired by a Big Pharma company which could then effect the Accelerated Approval process and gleen the benefit of the accretive acquistion themselves.
And on the subject of acquistion valuations, on February 01 2024 - Merck's (MSD) CEO Raay Davis went on record to say that Merck's acquisition "sweet spot " is US$ 10+ Billion, as had been suggested as Big Pharma's sweet spot around 12 month ago.